Charles River Laboratories International, Inc. Common Stock (CRL)

Charles River Laboratories International (NYSE:CRL) raised its 2026 revenue and earnings outlook after third-quarter organic revenue growth accelerated to 4.7%, supported by demand for safety assessment and manufacturing testing services. Non-GAAP earnings per share rose 27.2% to $3.09, exceeding t

Lab services company Charles River Laboratories (NYSE:CRL) reported revenue ahead of Wall Street’s expectations in Q3 2026, but sales fell by 2.2% year on ye...

Pharma clients resume R&D spending as organic growth returns.

Lab services company Charles River Laboratories (NYSE:CRL) announced better-than-expected revenue in Q3 2026, but revenue fell by 2.2% year on year to $982.7...

Lab services company Charles River Laboratories (NYSE:CRL) will be announcing earnings results this Wednesday before the bell. Here’s what to look for. Charl...

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry...

Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the man...

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, including Charles River Laboratories (NY...

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor exec...

Charles River Laboratories International (NYSE:CRL) outlined a strategy to accelerate growth, expand margins and modernize its operations during its 2026 Investor Day, setting financial targets through 2030 that include 5% to 7% organic revenue growth, an approximately 24% non-GAAP operating margin

What Happened? Shares of lab services company Charles River Laboratories (NYSE:CRL) jumped 5.7% in the afternoon session after the company outlined long-term...

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea...

What Happened? Shares of lab services company Charles River Laboratories (NYSE:CRL) jumped 3.6% in the afternoon session after the company announced the laun...

What a fantastic six months it’s been for Charles River Laboratories. Shares of the company have skyrocketed 79.5%, hitting $272.74. This was partly thanks t...

Even if there's no clarity on the Clarity Act, Coinbase and Circle could still power higher over the next 12 months.